… VSL#3 are derived from in vitro studies and animal models, and further study is warranted into
the immune responses associated with VSL… response following oral treatment with VSL#3. …

… of VSL#3 in chronic diseases of animals and humans (including children). We found that
VSL#… This review seeks to provide an overview of the role of VSL#3 in various kinds of diseases …

Aim : To investigate the effects of a probiotic formulation, VSL#3, on gastrointestinal transit
and symptoms of patients with Rome II irritable bowel syndrome with predominant diarrhoea. …

… The probiotic preparation used in this study was VSL#3 (VSL pharmaceuticals Inc., Fort
Lauderdale, USA). VSL#3 3 g sachets contain 300 billion bacteria/g, comprising four strains of …

… conducted with VSL#3, a product that has proven to be effective for the treatment and
prevention of pouchitis ( 3 ). The aim of this investigation was to assess whether, by adding VSL#3 …

… VSL#3 has been reported to achieve remission/response in children with mild to moderate
UC.24, 25 Although there is growing data on the efficacy of VSL… and safety of VSL#3 in mild-to…

… VSL#3 seems more safer than fecal microbiota transplantation, because serious adverse
events were not reported in the VSL… and that of mixed probiotics VSL#3. However, the use of …

Objectives: To evaluate whether chronic therapy with probiotics affects plasma levels of
cytokines and oxidative/nitrosative stress parameters, as well as liver damage, in patients with …

Background & Aims Probiotic formulations of single species of bacteria have not been effective
in preventing the recurrence of Crohn’s disease after surgery. We investigated the ability …

… The primary objective of this study was to monitor the clinical efficacy of VSL#3 therapy in …
to investigate the safety of VSL#3 in children with UC. Prior to and post-VSL#3 treatment serum …